Table 1.
Patient characteristics at treatment baseline.
| Av Obs. | Baseline | |
|---|---|---|
| Age, years, median (IQR) | 43 | 68.87 (61.46–75.78) |
| Male, n (%) | 43 | 23 (53.48) |
| Disease Duration, years, median (IQR) | 43 | 12.66 (7.61) |
| ILD duration, years, median (IQR) | 43 | 5.55 (5.13) |
| Follow-up, months, median (IQR) | 43 | 19.1 (14.92) |
| Rheumatoid factor positivity, n (%) | 43 | 38 (88.37) |
| ACPA positivity, n (%) | 43 | 35 (81.40) |
| HRCT pattern, n (%) | 43 | |
| UIP | 25 (58.14) | |
| NSIP | 5 (11.62) | |
| LIP | 2 (4.65) | |
| CPFE | 1 (2.33) | |
| Indeterminate | 10 (23.26) | |
| Baseline DLCO, mean (SD) | 27 | 65.81 (16.92) |
| Baseline FVC, mean (SD) | 30 | 88.76 (24.03) |
| Prescribed JAKi, n/%) | 43 | |
| Baricitinib | 28 (65.12) | |
| Filgotinib | 3 (6.98) | |
| Tofacitinib | 9 (20.93) | |
| Upadacitinib | 3 (6.98) | |
| Use of DMARD before JAKi, n (%) | 43 | |
| Methotrexate | 32 (74.41) | |
| Leflunomide | 3 (6.97) | |
| TNFalpha inhibitors | 19 (44.19) | |
| Rituximab | 12 (27.91) | |
| Abatacept | 16 (38.10) | |
| Tocilizumab | 13 (30.23) | |
| JAKi + Methotrexate, n (%) | 43 | 16 (37.21) |
| Glucorticoids n (%) | 43 | 26 (60.47) |
Abbreviations: ACPA: anti-citrullinated peptide antibodies; CPFE: combined pattern pulmonary fibrosis and emphysema; DLCO: diffusing capacity of lung for carbon monoxide; DMARD: disease-modifying anti-rheumatic drug; FVC: forced vital capacity; JAKi: Janus kinase inhibitors; IQR: interquartile range; ILD: interstitial lung disease; LIP: lymphocytic interstitial pneumonia; NSIP: non-specific interstitial pneumonia; UIP: usual interstitial pneumonia; TNF: tumor necrosis factor.